Question-and-Answer Session
Operator
(Operator Instructions) Our first question comes from the line of Ross Muken. Please proceed.
Ross Muken - Deutsche Bank
Good afternoon gentlemen.
Jay Flatley
Hi, Ross.
Christian Henry
Hi, Ross.
Ross Muken - Deutsche Bank
Congratulations, wonderful quarter. There was a bit of concern coming into the quarter I think in general about slowdown on the array side of the business obviously that is the antithesis of what we saw. Can you talk a bit about aside from sort of the obvious in terms of some of these new studies that are coming along and the size increases? What we are seeing in some of the nontraditional markets for array?
And then sort of compare and contrast, what you are seeing in terms of incremental demand is it from existing customers, new customers? Just help us think about kind of the dynamics there and what's continuing that pretty attractive growth trajectory?
Jay Flatley
Sure. As I mentioned in the script, Ross, I think, as we look forward in the array market, we continue to feel really good about what's happening in Whole-Genome Association Studies as these very large projects come through, we are going to continue to see greater adoption of new versions of our chip particularly as we begin to sequence these very large numbers of samples. We'll to start identifying rare variance and that has the potential to create wholly new versions of our chip that have much richer content. And so, we expect that will pass through the genotyping market to continue.
We do expect very strong growth in what we call the emerging segments in the applied market and in the consumer markets. In the applied side, we now have three different chips that we are shipping, a bovine chip, an equine chip and a canine chip. We are working very broadly with a large number of collaborators in other potential organisms. In fact we have a very large company in the office today talking about a particular crop that they want to sequence and ultimately put onto chips. So, it's a very exciting, I think, long-range and high-growth opportunity.
We also continue to be very bullish about what's going to happen in the consumer space despite the fact that there has been a lot of regulatory noise in this space. We are confident that those issues are going to get resolved over the next six to 18 months or so and that there is going to be a very clear path, where consumers can get access to their genetic information and overtime as those prices comedown, we think the market is very elastic and it will grow significantly.
- To read the full transcript on Seeking Alpha, click here »
